Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21797964 | 0.89 | RIPK1 (0.68) | RIPK1 | |
| SCHEMBL20254439 | 0.89 | RIPK1 (0.77) | RIPK1 | |
| SCHEMBL24220438 | 0.86 | RIPK1 (0.58) | RIPK1 | |
| SCHEMBL21797968 | 0.85 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL18248420 | 0.83 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL18255208 | 0.83 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL30322076 | 0.82 | RIPK1 (0.72) | RIPK1 | |
| SCHEMBL20254571 | 0.82 | RIPK1 (0.72) | RIPK1 | |
| SCHEMBL24018700 | 0.82 | RIPK1 (0.55) | RIPK1 | |
| SCHEMBL24018696 | 0.81 | RIPK1 (0.49) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851433-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11851433-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-3625234-B1 | HEXAHYDROPYRAZOLO [1,2-A] DIAZEPINONES AND RELATED HETEROCYCLES AS INHIBITORS OF RIP-1 KINASE | DENALI THERAPEUTICS INC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20220024938-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11174262-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2021-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024938-A1 | Compounds, Compositions and Methods | BAX, CASP3, CASP8 | RIPK1 263/4885 |
| US-11174262-B2 | Compounds, compositions and methods | BAX, CASP3, CASP8 | RIPK1 263/4885 |
| US-11851433-B2 | Compounds, compositions and methods | BAX, CASP3, CASP8 | RIPK1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.